Show simple item record

dc.contributor.authorMendizabal, Manuel.
dc.contributor.authorHaddad, Leila.
dc.contributor.authorGallardo, Patricia.
dc.contributor.authorFerrada, Alejandro.
dc.contributor.authorSoza, Alejandro.
dc.contributor.authorAdrover, Raul.
dc.contributor.authorAravena, Edmundo.
dc.contributor.authoret al.
dc.date.accessioned2020-03-02T18:29:55Z
dc.date.available2020-03-02T18:29:55Z
dc.date.issued2017-09-01
dc.identifier.citationJ Med Virol. 2017 Sep;89(9):1590-1596.en_US
dc.identifier.issn0146-6615
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/836
dc.description.abstractInformation about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectAntiviral agentsen_US
dc.subjectDisease controlen_US
dc.subjectHepatitis C virusen_US
dc.subjectPublic policyen_US
dc.titleOmbitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record